Huang, J., Hu, X., Wang, H., Guo, J., Zhang, H., Dong, P., Xue, W. (2026). Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.422